Streetbeat News

Products Services

ARM

The article discusses the stock of Arm Holdings PLC (NASDAQ:ARM), highlighting its recent overbought status and potential price reversal. The stock may find support at $163 due to trading psychology and seller's remorse.

Portfolio Pulse from Mark Putrino

September 16, 2024 | 5:53 pm

GEV

GE Vernova has been selected to provide an integrated Battery Energy Storage System (BESS) for the second stage of Quinbrook's Supernode project in Queensland, Australia. This project aims to efficiently store wind and solar energy, making it one of the largest BESS installations in Australia.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 5:52 pm

AFRM

Affirm's stock price is rising following the announcement that its services are now available for Apple Pay users, potentially increasing its user base and transaction volume.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 5:50 pm

AAPL

ARM

MU

NVDA

QRVO

SOXX

WOLF

Tech stocks fell as concerns over Apple's iPhone 16 demand impacted chipmakers, with Apple shares dropping over 3% and Arm Holdings plunging more than 5%. The semiconductor sector, tracked by the iShares Semiconductor ETF, declined by 2.2%. Meanwhile, bonds rose on expectations of a 0.5% Fed rate cut.

Portfolio Pulse from Piero Cingari

September 16, 2024 | 5:48 pm

NUVL

Nuvalent, Inc. (NASDAQ:NUVL) presented promising data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024, leading to a 22.6% stock price increase. The company is also seeking to raise $350 million through an equity offering.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 5:44 pm

OPTHF

PBM

Psyence Biomedical Ltd. (NASDAQ:PBM) is advancing its psychedelic-based mental health solutions with a Phase IIb trial in Australia and the acquisition of Clairvoyant. The company is also partnering with Optimi Health (OTC:OPTHF) for psilocybin supply, aiming for significant data readouts in 2025.

Portfolio Pulse from Juan Spínelli

September 16, 2024 | 5:42 pm

ADBE

CRM

Adobe Inc (NASDAQ:ADBE) exceeded Q3 expectations but issued a cautious Q4 guidance, causing concerns about competition and market conditions. Despite strong revenue growth and AI integration, Adobe's forecast fell short of estimates, impacting its stock.

Portfolio Pulse from Upwallstreet

September 16, 2024 | 5:41 pm

LLY

Eli Lilly's Ebglyss, a new eczema treatment, has received FDA approval. The drug targets inflammation and is suitable for patients 12 years and older. Clinical trials showed significant improvement in skin clarity and itch relief. LLY stock saw a slight increase following the news.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 5:36 pm

AAPL

PCG

PG&E customers can now access their electricity usage data through Apple's Home app on various Apple devices, allowing them to make informed decisions about their energy consumption.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 5:36 pm

BMRN

BioMarin Pharmaceutical shares are experiencing a decline due to strong clinical data from Ascendis Pharma's competing dwarfism drug.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 5:26 pm